Trastuzumab-DM1 (Kadcyla®, Genentech, San Francisco) is an example of an ADC developed against ErbB2-overexpressing cancers in which a cytotoxic drug (Emtansine) is chemically conjugated to humanized anti-ErbB2 monoclonal antibody Trastuzumab (Genentech) [2]. Here, ERBB2 is linked to cancer.